Aligos Therapeutics Income Statement (2021-2025) | ALGS

Income Statement Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 0.91M1.54M1.54M0.37M2.57M3.69M4.11M3.54M2.58M4.29M2.15M2.01M0.69M1.06M1.25M0.61M0.31M0.96M0.74M
Operating items
Research & Development 22.87M24.55M28.13M28.60M31.68M16.51M17.79M19.10M18.14M16.78M15.87M22.26M16.37M21.10M16.77M16.03M14.50M13.98M23.94M
Selling, General & Administrative 5.78M6.56M6.47M9.72M6.45M7.58M5.26M7.12M8.51M9.25M6.44M6.42M6.67M6.38M4.63M5.16M5.05M5.56M5.17M
Other Operating Expenses 0.11M-0.23M0.07M0.18M-0.01M0.52M0.28M0.84M1.00M1.11M1.06M0.24M1.58M1.23M1.07M0.57M0.88M1.21M1.08M
Operating Expenses 28.65M31.11M34.60M38.31M38.13M24.09M23.05M26.22M26.64M26.03M22.31M28.68M23.03M27.48M21.40M21.19M19.55M19.53M29.10M
Operating Income -27.74M-29.57M-33.07M-37.95M-35.56M-20.39M-18.95M-22.68M-23.92M-19.14M-19.07M-26.00M-22.05M-26.41M-20.13M-20.56M-19.24M-18.57M-28.36M
EBIT -27.74M-29.57M-33.07M-37.95M-35.56M-20.39M-18.95M-22.68M-23.92M-19.14M-19.07M-26.00M-22.05M-26.41M-20.13M-20.56M-19.24M-18.57M-28.36M
Net income details
EBT -27.63M-29.79M-33.00M-37.77M-35.56M-19.88M-18.66M-21.84M-22.92M-18.03M-18.01M-27.92M-34.84M5.25M-19.17M-82.12M43.13M-15.68M-31.48M
Tax Provisions 0.04M0.03M0.13M-0.06M0.05M0.05M-0.04M0.05M0.04M0.76M0.03M-0.03M0.02M0.19M0.09M0.03M0.04M0.18M0.06M
Profit After Tax -27.67M-29.82M-33.12M-37.71M-35.62M-19.92M-18.62M-21.89M-22.95M-18.79M-18.04M-27.89M-34.86M5.06M-19.26M-82.15M43.09M-15.86M-31.54M
Income from Continuing Operations -27.67M-29.82M-33.12M-37.71M-35.62M-19.92M-18.62M-21.89M-22.95M-18.79M-18.04M-27.89M-34.86M5.06M-19.26M-82.15M43.09M-15.86M-31.54M
Consolidated Net Income -27.67M-29.82M-33.12M-37.71M-35.62M-19.92M-18.62M-21.89M-22.95M-18.79M-18.04M-27.89M-34.86M5.06M-19.26M-82.15M43.09M-15.86M-31.54M
Income towards Parent Company -27.67M-29.82M-33.12M-37.71M-35.62M-19.92M-18.62M-21.89M-22.95M-18.79M-18.04M-27.89M-34.86M5.06M-19.26M-82.15M43.09M-15.86M-31.54M
Net Income towards Common Stockholders -27.67M-29.82M-33.12M-37.71M-35.62M-19.92M-18.62M-21.89M-22.95M-18.79M-18.04M-27.89M-34.86M5.06M-19.26M-82.15M43.09M-15.86M-31.54M
Additional items
EPS (Basic) -0.74-0.79-0.78-0.91-0.84-0.47-0.44-0.51-0.53-0.43-10.370.39-5.580.81-3.07-13.115.12-1.53-3.04
EPS (Weighted Average and Diluted) -0.78-0.84-0.47-0.44-0.51-0.53-0.43-10.370.39-5.580.81-3.07-13.11-2.11-1.53-3.04
Shares Outstanding (Weighted Average) 37.43M37.62M42.40M39.86M42.51M42.67M42.76M42.70M42.91M43.22M1.74M2.56M156.15M156.44M6.27M6.26M10.37M
Shares Outstanding (Diluted Average) 42.40M42.51M42.67M42.76M42.70M42.91M43.22M1.74M2.56M156.15M156.65M6.27M6.26M10.37M
EBITDA -27.71M-29.84M-33.12M-37.01M-35.86M-20.08M-18.51M-21.64M-22.86M-18.79M-18.04M-27.84M-34.93M5.08M-19.18M-82.28M43.08M-15.89M-31.50M
Tax Rate -0.16%-0.09%-0.38%0.15%-0.15%-0.24%0.23%-0.22%-0.17%-4.20%-0.16%0.11%-0.07%3.60%-0.47%-0.03%0.10%-1.18%-0.18%